University of Minnesota - Masonic Cancer Center
Minneapolis, MN
Accepting patients
MonumenTAL-6
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
- Bispecific Antibody
- CD3
- GPRC5D
- Randomization
- Phase 3
Accepting patients
Low-Dose Radiotherapy for Bone Metastases
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- Radiation
- Phase 2
Accepting patients
IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Natural Killer Cells (Allogeneic)
- Phase 1/2
Accepting patients
UCB Transplant with Myeloablative Prep
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Myeloablative Allo Stem Cell Transplant
Myeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematological Disorders
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Post-Transplant Cytoxan
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Xanthine Oxidase Inhibitor
- Phase 2